TTR and Cachexia: Cachexia in patients with terminal cancer presents as significant loss of skeletal muscle and adipose tissue.12,13 Pathophysiologically, cachexia is characterized by a negative protein–energy balance resulting from decreased oral intake and metabolic abnormalities.14 In particular, pancreatic cancer often leads to reduced oral intake, which readily causes cachexia and deteriorates the patient’s general condition.15 Therefore, we investigated the relationship between serum TTR, Alb, and CRP levels—cachexia-related proteins—and survival (in days).